Compare Infosys Limited (INFY) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Natera Inc. Common Stock — how do they compare? Infosys Limited trades at $11.76 (market cap $46.25B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Infosys Limited pays a 4.56% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 26 Days and Natera Inc. Common Stock for 0 Days on average.
| INFY | NTRA | |
|---|---|---|
Market Cap | $46.25B | $57.03B |
Volume | 14,209,421 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $20.22 | $425.64 |
52-Week Low | $10.49 | $179.42 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $44.00B | $56.18B |
Dividend Yield | 4.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.40, up 5.26% today, with a bullish technical signal and strong profitability metrics including a 16.37% net margin and 32.12% ROE. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, signaling growth initiatives.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering modest upside. Risks include potential earnings volatility and competitive pressures in IT services. Analyst sentiment is mixed with 35% buy ratings, but strong cash flow and institutional interest support a stable investment case amid sector headwinds.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
